Open Access

Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis

  • Authors:
    • Sung-Eun Choi
    • Nara Jeon
    • Hoon Young Choi
    • Hyeon Joo Jeong
    • Beom Jin Lim
  • View Affiliations

  • Published online on: September 2, 2022     https://doi.org/10.3892/etm.2022.11585
  • Article Number: 648
  • Copyright: © Choi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tubulointerstitial fibrosis is characterized by accumulation of the extracellular matrix in the interstitium. Lysyl oxidase‑like 2 (LOXL2), a member of the lysyl oxidase family, is known for promoting cancer metastasis, invasion and stromal fibrosis in various organs. Our previous study demonstrated expression of LOXL2 in kidney podocytes and tubular epithelial cells, and the association between elevated LOXL2 and tubulointerstitial fibrosis. The present study evaluated the effect of LOXL2 inhibition using an inhibitory monoclonal antibody (AB0023) on tubulointerstitial fibrosis in a folic acid‑induced tubulointerstitial fibrosis mouse model. The association of LOXL2 with epithelial‑mesenchymal transformation‑related molecules was also evaluated in vitro using HK‑2 cells. The present data demonstrated that AB0023 prevented the progression of tubulointerstitial fibrosis significantly, as determined by trichrome and picro‑sirius red staining, as well as the total collagen assay. The mean expression of phosphorylated Smad2 and Smad4 was lower in the AB0023‑treated group although it was not statistically significant. Following transforming growth factor‑β (TGF‑β) challenge, LOXL2‑deficient HK‑2 cells exhibited significantly lower expression of the mesenchymal markers vimentin and fibronectin than control HK‑2 cells. In conclusion, LOXL2 inhibition ameliorates renal fibrosis through the TGF‑β/Smad signalling pathway.
View Figures
View References

Related Articles

Journal Cover

November-2022
Volume 24 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Choi S, Jeon N, Choi HY, Jeong HJ and Lim BJ: Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis. Exp Ther Med 24: 648, 2022
APA
Choi, S., Jeon, N., Choi, H.Y., Jeong, H.J., & Lim, B.J. (2022). Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis. Experimental and Therapeutic Medicine, 24, 648. https://doi.org/10.3892/etm.2022.11585
MLA
Choi, S., Jeon, N., Choi, H. Y., Jeong, H. J., Lim, B. J."Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis". Experimental and Therapeutic Medicine 24.5 (2022): 648.
Chicago
Choi, S., Jeon, N., Choi, H. Y., Jeong, H. J., Lim, B. J."Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis". Experimental and Therapeutic Medicine 24, no. 5 (2022): 648. https://doi.org/10.3892/etm.2022.11585